INCB054329

Catalog No.S8753 Batch:S875302

Print

Technical Data

Formula

C19H16N4O3
Molecular Weight 348.36 CAS No. 1628607-64-6
Solubility (25°C)* In vitro DMSO 70 mg/mL (200.94 mM)
Ethanol 70 mg/mL (200.94 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description INCB054329 is a structurally distinct bromodomain and extraterminal domain (BET) inhibitor with IC50 values of 44 nM, 5 nM, 9 nM, 1 nM, 28 nM, 3 nM, 119 nM and 63 nM for BRD2-BD1, BRD2-BD2, BRD3-BD1, BRD3-BD2, BRD4-BD1, BRD4-BD2, BRDT-BD1 and BRDT-BD2, respectively.
Targets
BRD3-BD2 [1] BRD4-BD2 [1] BRD2-BD2 [1] BRD3-BD1 [1] BRD4-BD1 [1] View More
1 nM 3 nM 5 nM 9 nM 28 nM
In vitro

INCB054329 shows no significant inhibitory activity against 16 non-BET bromodomains at 3 μM. In a panel of 32 hematologic cancer cell lines derived from acute myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma, the median 50% growth inhibition (GI50) value of INCB054329 is 152 nM (range, 26-5000 nM). In contrast to tumor cell lines, the GI50 value against T cells isolated from non-diseased donors stimulated ex vivo with IL-2 is 2.435 μM. Growth inhibition correlates with a concentration-dependent accumulation of cells in the G1 phase of the cell cycle. INCB054828 is also a selective kinase inhibitor of the FGFR 1, 2, and 3[1]. In myeloma cell lines, treatment with INCB054329 inhibits expression of c-MYC and induced HEXIM1. In both AML and lymphoma cell lines, INCB054329 induces apoptosis consistent with increased expression of pro-apoptotic regulators[2].
In vivo

INCB054329 exhibits high clearance in mice resulting in a short half-life. At exposures that effectively suppressed c-MYC, INCB054329 is found to be efficacious and well tolerated in both the KMS-12-BM and MM1.S xenograft models[1]. In vivo, oral administration of INCB054329 inhibits tumor growth in several models of hematologic cancers[2].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    Myeloma, AML, DLBCL cells

  • Concentrations

    --

  • Incubation Time

    72 h

  • Method

    Cell viability assay
Animal Study:

[1]
  • Animal Models

    KMS-12-BM tumors established in female Nu/Nu mice

  • Dosages

    3, 10, 30, or 100 mg/kg

  • Administration

    oral

Selleck's INCB054329 has been cited by 5 publications

Inhibition of BET Family Proteins Suppresses African Swine Fever Virus Infection [ Microbiol Spectr, 2022, 10(4):e0241921] PubMed: 35758684
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection [ Cell, 2021, S0092-8674(21)00354-8] PubMed: 33811809
Bromodomain and Extraterminal Inhibition Blocks Inflammation-Induced Cardiac Dysfunction and SARS-CoV-2 Infection (Pre-Clinical) [ bioRxiv, 2021, 10.1101/2020.08.23.258574] PubMed: N/A
BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma [ Oncol Rep, 2020, 44(6):2475-2486] PubMed: 33125143
Predicting response to BET inhibitors using computational modeling: A BEAT AML project study. [ Leuk Res, 2019, 77:42-50] PubMed: 30642575

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.